24/7 Market News Snapshot 20 February, 2025 – Cel-Sci Corporation (NYSE:CVM)

February 20, 2025

DENVER, Colo., 20 February, 2025 (247marketnews.com) – (NYSE:CVM) are discussed in this article.
CEL-SCI Corporation has recently experienced a positive shift in its stock performance, with shares opening at $0.524 and climbing to $0.587, marking an increase of approximately 14.49%. This growth follows a previous closing price of $0.513, signaling a robust interest from investors as evidenced by a trading volume of 5.39 million shares. Technical analysis indicates potential resistance around the $0.60 mark and support near $0.52. Should the buying momentum persist, there may be opportunities for further advancement; however, investors are advised to closely monitor market fluctuations and confirm trends prior to committing significant resources.

In conjunction with its favorable market activity, CEL-SCI announced the upcoming launch of a critical 212-patient Confirmatory Registration Study for Multikine (Leukocyte Interleukin, Injection). This study is particularly aimed at newly diagnosed patients suffering from locally advanced head and neck cancer. The initiative is designed to validate the promising results observed in prior Phase 3 trials, where Multikine demonstrated a remarkable increase in the five-year survival rate from 45% in the control group to 73% among treated individuals.

This Registration Study will recruit clinical sites and distinguished investigators across multiple countries over three continents, with full enrollment anticipated by the second quarter of 2026. The strategy aims for early therapeutic approval based on preliminary data related to tumor responses, which could set a new standard in cancer care.

CEO Geert Kersten emphasized the importance of this study, noting a 95% statistical likelihood of success based on earlier outcomes. The initiative aims to enhance patient immunity before surgical intervention, thereby improving long-term survival rates. With Multikine having been administered to over 740 patients under strict clinical guidelines, CEL-SCI’s commitment to pioneering advancements in oncology remains resolute, promising to transform treatment regimens for head and neck cancer patients.

Related news for (CVM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.